Tarsus Pharmaceuticals, Inc.
corporate_fare Company Profile
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for TARS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-03, rated 8/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 18 rated 8 or above. Recent SEC coverage for TARS spans 10-Q, 8-K/A, 8-K, 10-K.
Recent high-impact activity:
- Tarsus 10-Q: Q3 XDEMVY Sales $194.6M, $668.3M Net Loss on $632.2M IPR&D Charge
- XDEMVY Sales Jump 64% to $194.6M, but $632M IPR&D Charge Drives $668M Quarterly Loss
- Tarsus Files Alkeus Financials: $564.8M IPR&D Charge and Going Concern Flag
- Tarsus Closes $450M Alkeus Acquisition, Adds Phase 3 Stargardt Asset
- Tarsus Q2 2026: XDEMVY Sales Surge 69% to $174M, Operating Cash Flow Turns Positive, and $125M PIPE Priced at $56
Financial Snapshot
Short Interest & Short Volume
6.94 days to coverFINRA reported short interest of 6,066,524 shares in TARS as of the October 30, 2026 settlement, a 5.9% increase from the prior period — about 6.9 days to cover at its recent average daily volume. On November 20, 2026, 60.7% of TARS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for TARS, detected from its recent SEC filings · based on capital-structure filings through 2026-08-06.
$125M PIPE Priced at $56.00 · Strategic Investor Participation
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →